Tumor metabolism and severe pneumonia pipeline products

Field	-
Country or region	Guangdong, China
Project requirement	Capital demand: 30 million yuan in this round of financing.. Expansion demand: The product has entered the clinical trial stage, and it is expected to establish a wholly-owned subsidiary of nano antibody and RNA in June 2024, and apply for major project subsidies in Shenzhen
Project details	The company integrates the three major technology platforms of RNA drugs, nano antibodies, cell and gene therapy, and can quickly validate and transform drugs for different targets. The R&D projects that the team has participated in have successfully entered the clinical trial stage. The R&D team is led by a professor of Shenzhen International Graduate School of Tsinghua University and director of the former Shenzhen Key Laboratory of Health Science and Technology. Shenzhen International Graduate School of Tsinghua University participates in promoting the transformation of R&D results, and takes targeting tumor metabolic reprogramming as the positive direction of developing new anti-tumor therapies. A number of pipeline products such as broad-spectrum anti-tumor small nucleic acid drugs, double-specific nanoantibodies for the treatment of various tumors, small nucleic acid drugs for the treatment of severe pneumonia, and AMD eye drops for the treatment of VEGF targets have been developed. The product has received several rounds of financing, and a wholly-owned subsidiary of nano antibody and RNA drugs will be established in 2024.
Contact information	Xuxiang Zhao , Chairman
Release time	2024-03-15